Search the Newsreel

Instacart's Smart Trolleys are Now Available at Morrisons Preston in the UK

Launching in Preston, Morrisons is the first UK retailer to deploy Instacart's AI-powered Caper smart trolleys SAN FRANCISCO and BRADFORD, England, July 28, 2026 /PRNewswire/ -- Instacart (NASDAQ: CART), the leading grocery technology company in North America, and Morrisons, one of the UK's largest …

Morgan Stanley Downgrades MapLight Therapeutics to Equalweight From Overweight, $34 PT

Morgan Stanley has downgraded MapLight Therapeutics (MPLT) from Overweight to Equalweight, setting a price target of $34. This decision comes after recent news regarding the company, including a significant drop in share price following the failure of its schizophrenia drug in a once-daily test, …

Morgan Stanley Reaffirms "Equal Weight" Rating for Maplight Therapeutics (NASDAQ:MPLT)

Does MapLight Therapeutics’ (MPLT) Dual Symptom And Cognitive Data Hint At A Differentiated Schizophrenia Strategy?

Top Midday Decliners

MapLight Therapeutics' (MPLT) shares tumbled 68% even after the company said its phase 2 trial of ML PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade …

MapLight dives despite positive data for schizophrenia drug

MapLight Therapeutics shares fell by 66% after releasing Phase 2 study results for a schizophrenia drug, despite the data showing positive results regarding general safety and efficacy. Investors were reportedly concerned that the drug's efficacy profile would not be competitive with Bristol Myers Squibb's …

MapLight Therapeutics Says Phase 2 Schizophrenia Trial Meets Primary Endpoint

MapLight Therapeutics announced that its Phase 2 trial for a new schizophrenia treatment successfully met its primary endpoint. This positive outcome indicates potential progress in developing novel therapies for schizophrenia, building on the company's research efforts.

MapLight Reports Results From Phase 2 ZEPHYR Trial Of ML-007C-MA; Stock Down More Than 60%

(RTTNews) - MapLight Therapeutics (MPLT) announced positive topline results from its Phase 2 ZEPHYR trial evaluating ML-007C-MA in adults with an acute exacerbation of schizophrenia. The trial met its primary endpoint, with the 210/3 mg twice-daily dose demonstrating a statistically significant and clinically meaningful …

MapLight Therapeutics stock tumbles 50% on mixed phase 2 schizophrenia data (MPLT:NASDAQ)

MapLight Therapeutics (MPLT) stock dropped 50% in premarket trading despite positive Phase 2 trial results for its schizophrenia drug candidate. The decline was due to the once-daily dosing regimen failing to achieve statistical significance on the primary endpoint, although the trial did meet its …

MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia

MapLight Therapeutics announced positive topline results from its Phase 2 ZEPHYR trial for ML-007C-MA in schizophrenia, meeting its primary endpoint with a statistically significant improvement in PANSS total score at the 210/3 mg BID dose. The trial also showed significant improvements in cognitive performance …

MapLight Therapeutics (Nasdaq: MPLT) hits key Phase 2 goal in schizophrenia

MapLight Therapeutics announced positive topline results for its Phase 2 ZEPHYR trial of ML-007C-MA in adults with acute exacerbation of schizophrenia. The 210/3 mg twice-daily dose met the primary endpoint with a statistically significant reduction in PANSS total score and showed clinically meaningful improvement …

MapLight Therapeutics Inc (MPLT) Cash Flow

This article provides MapLight Therapeutics Inc (MPLT) cash flow statement data for FY2026Q1, including operating, investing, and financing cash flows. It breaks down key financial metrics, such as a -51.18M operating cash flow and a 67.01M investing cash flow, and offers FAQs explaining cash …

MPLT|MapLight Therapeutics Inc|Price:11.550|Chg%:-0.030

MPLT|MapLight Therapeutics Inc|Price:11.980|Chg%:-0.200

CART|Maplebear Inc|Price:42.210|Chg%:-0.320

This article provides a detailed introduction to Maplebear Inc. (CART), operating as Instacart, highlighting its business model as a grocery technology company in North America. It covers the company's partnerships with retailers, its Instacart Platform offerings, financial data, key executives, and major shareholders. The …

Maple Leaf Foods (TSE:MFI) Given a C$36.00 Price Target by Canadian Imperial Bank of Commerce Analysts

MPLT Stock Plunges 73% — Wipes Out Over $1B In Market Cap After Trial Miss On Once-Daily Dose

Maplebear Inc. $CART Stock Holdings Boosted by Renaissance Technologies LLC

MapLight Therapeutics (MPLT) Rally Puts Its CNS Story And Valuation In Focus

MapLight Therapeutics (MPLT) has experienced a significant rally in 2024, with its share price up 118.01% year-to-date, drawing attention to its clinical-stage central nervous system pipeline. Currently trading at $36.56 with a market value of $1.66 billion, the stock's price-to-book ratio of 4.1x is …

MapLight Therapeutics, Inc. Revenue Breakdown – NASDAQ:MPLT

This article provides a company overview for MapLight Therapeutics, Inc. (MPLT) on the NASDAQ, focusing on its financial data. It covers various fundamental and statistical aspects, including statements, dividends, earnings, and segments, while noting that market data is provided by ICE Data Services and …

Is MapLight Therapeutics (MPLT) Fully Valued As Its Shares Hold Near $36.56?

MapLight Therapeutics (MPLT) shares have seen significant gains recently, with a year-to-date return of 118.01%, bringing its stock price to $36.56. The company currently trades at a Price-to-Book (P/B) ratio of 4.1x, which is higher than its peer average of 3.5x and the broader …

Maplebear Inc (CART) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Maplebear Inc (CART), highlighting its current valuation score and P/E ratio. Maplebear Inc. has a current valuation score of 5.62, ranking 433 out of 485 in the Software & IT Services industry. Its P/E ratio stands at …

Maplebear Inc (CART) Institutional Confidence

Maplebear Inc (CART) has an institutional shareholding score of 7.00, placing it 139th out of 485 in the Software & IT Services industry. The institutional shareholding proportion is 85.50%, which is an 18.69% decrease quarter-over-quarter. James Simons is the largest institutional shareholder, holding 0.66% …

PT MAP Aktif Adiperkasa Tbk Revenue Breakdown – IDX:MAPA

Enterprise value to EBIT forward of Maplebear Inc. – BMV:CART

This article provides financial information for Maplebear Inc. (BMV:CART), specifically focusing on its enterprise value to EBIT forward. It is presented in the context of TradingView's platform, offering various financial tools and data. The information is sourced from ICE Data Services, FactSet, and Quartr …

Mapfre SA (MPFRF) Q2 2026 Earnings Call Highlights: Strong Profitability and Strategic ...

This article first appeared on GuruFocus. Net Profit: EUR624 million, reflecting strong performance across core markets. Premiums: Up over 1%, with a positive currency effect beginning to emerge. Non-Life Combined Ratio: 92.8%, improved year-on-year and quarter-on-quarter. Adjusted ROE: Well over 13%, on track to …

Biggest Mover Friday: Safety Insurance Stock Soars 40% after $1.54B buyout deal

This article first appeared on GuruFocus. Safety Insurance Group (NASDAQ:SAFT) shares surged about 40% on early Friday after the insurer agreed to be acquired by Mapfre in an all-cash transaction valued at approximately $1.54 billion. Under the terms of the agreement, Safety Insurance shareholders …

How Instacart Is Expanding Growth Beyond Grocery Delivery Services

Maplebear Inc. CART, doing business as Instacart, is moving beyond its roots as a grocery-delivery marketplace. Its platform now spans enterprise software, retail media, artificial intelligence and connected-store tools. The investor question is whether these businesses can deepen retailer relationships and support more durable …

Is CART Stock Attractive After Strong Growth and Margin Pressure?

Maplebear Inc. CART, doing business as Instacart, presents a balanced investment setup after a quarter that mixed healthy marketplace growth with visible margin pressure. The stock's current valuation partly reflects that tension. CART trades below its own historical sales multiple, but still at a …

Canaccord raises MapLight Therapeutics price target on trial data By Investing.com

Canaccord has increased its price target for MapLight Therapeutics (NASDAQ: MPLT) to $43 from $35, maintaining a Buy rating, ahead of top-line data from its Phase 2 ZEPHYR trial for ML-007C-MA in mid-August 2026. Other firms like UBS, Needham, and Raymond James have also …

Stocks to watch: SGX, SIA Engineering, Mapletree Industrial Trust, Suntec Reit, ESR Reit

Safety Insurance Group, Inc. Enters Into Merger Agreement With Mapfre for $1.54 Billion

Transaction Delivers Significant Value for Shareholders and Positions Safety for Long-Term Growth Across New England BOSTON, July 23, 2026--(BUSINESS WIRE)--Safety Insurance Group Inc. (NASDAQ:SAFT) ("Safety"), one of the leading property and casualty insurers in Massachusetts and across New England, today announced that it has …

Possible Bearish Signals With MapLight Therapeutics Insiders Disposing Stock

Insiders at MapLight Therapeutics (NASDAQ: MPLT) have sold a significant amount of stock over the past year, totaling US$6.3 million, compared to US$694k in purchases. The recent insider selling, particularly US$3.8 million worth of shares dumped in the last three months with no corresponding …

Form 144 Maplebear Inc. For: 22 July By Investing.com

This article reports on the filing of Form 144 for Maplebear Inc. on July 22, 2026. Form 144 is a notice filed with the SEC by an affiliate of a company to announce their intention to sell restricted securities. The article does not provide …

Maplebear Inc. (CART) insider files to sell 18,390 shares via cashless option exercise

Maplebear Inc. insider Morgan Fong has filed a Form 144 to sell up to 18,390 shares of common stock, valued at approximately $815,398.00, through a cashless employee stock option exercise. The proposed sale date is July 22, 2026. The filing also revealed that 14,033 …

MapLight Therapeutics general counsel sells $607,870 in shares

MapLight Therapeutics General Counsel Kristopher Hanson sold $607,870 worth of company stock between July 15 and July 17, 2026. These sales were not discretionary but rather "sell to cover" transactions to satisfy tax obligations from restricted stock unit vesting. The company has also recently …